Meera Patel

Meera Patel

Auto-generated profile, based on publicly available information

Meera Patel

Baylor College of Medicine, McNair Campus, Houston, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
UVUlka N. Vaishampayan
Ulka N. Vaishampayan
ATArchana Thakur
Archana Thakur
WCWei Chen
Wei Chen
ADAbhinav Deol
Abhinav Deol
MPMeera Patel
Meera Patel
LLLawrence G Lum
Lawrence G Lum
Purpose: A phase II study was conducted to evaluate the safety and efficacy of the combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and programmed death 1 inhibitor, pembrolizumab. Patients and Methods: Patients with metastatic castration-resistant prostate cancer (mCRPC) with 0 to 1 performance status and normal liver, kidney, and marrow function, pre- or post-docetaxel chemotherapy were eligible. Primary endpoint was 6-month progression-free survival (PFS). Peripheral blood mononuclear cells were obtained by a single apheresis, shipped to University of Virginia, activated with OKT3 and expanded for 14 days in IL2, harvested, and armed with HER2Bi and cryopreserved. HER2 BATs were infused twice weekly for 4 weeks and pembrolizumab was administered every 21 days for a maximum duration of 6 months starting 1 to 3 weeks prior to HER2 BATs infusion. Results: Fourteen patients were enrolled with a median age of 69 (range 57–82 years) and median PSA of 143.4 (range 8.2–4210 ng/dL). Two patients had peritoneal metastases, 1 had lymph node (LN) only metastases and 11 had bone metastases of which 7 had bone and LN metastases. All were pretreated with androgen receptor axis targeted agents and 7 (50%) had prior docetaxel chemotherapy. The toxicities were grade1–2 infusion reactions with fever, chills, headaches, nausea and/or myalgias. Primary endpoint of 6 month PFS was achieved in 5 of 14 patients (38.5%; 95% confidence interval, 19.5%–76.5%). Median PFS was 5 months and median survival was 31.6 months. Conclusions: The safety and promising efficacy makes this combination worthy of future investigation in mCRPC.

10 April 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
HJHee-Jin Jang
Hee-Jin Jang
MPMeera Patel
Meera Patel
DWDaniel Y. Wang
Daniel Y. Wang
SKSung Wook Kang
Sung Wook Kang
JCJong Min Choi
Jong Min Choi
BBBryan M. Burt
Bryan M. Burt
Purpose: Immune checkpoint inhibitors (ICI) have limited efficacy in pleural mesothelioma. We investigated the role of Dickkopf WNT signaling pathway inhibitor 3 (DKK3) in overcoming treatment resistance. Patients and Methods: We performed preclinical studies to elucidate DKK3’s role in ICI-resistant mouse mesothelioma. Based on these findings, we conducted a single-arm, phase II clinical trial of a combination of Ad-SGE-DKK3 and nivolumab for chemotherapy-refractory epithelioid pleural mesothelioma, with the objective response rate as the primary outcome. Results: DKK3 was significantly reduced in human epithelioid mesothelioma. Overexpression of DKK3 in cancer cells activated the p53 pathway, enhanced glycolysis, increased surface PD-L1, and reduced extracellular vesicle secretion and the colony-stimulating factor 1. DKK3 sensitized the tumor immune microenvironment to ICIs and enabled the eradication of tumors by PD-1 blockade. In our trial, 12 patients received intratumoral Ad-SGE-DKK3 plus intravenous nivolumab. The objective response rate was 16.6%, and 41.7% had stable disease, for a 58.3% rate of durable clinical response. The median overall survival was 14.5 months, and the median progression-free survival was 4.5 months. Grade 3 adverse events occurred in 41.7% of patients. Serial tumor biopsies and serum analyses revealed that patients with durable clinical response had increased tumor-infiltrating bulk and effector memory CD8 T cells, reduced circulating memory CD8 T cells, and sustained lower soluble mesothelin and the colony-stimulating factor 1 levels compared with progressors. Conclusions: Combination Ad-SGE-DKK3 plus nivolumab demonstrated a tolerable safety profile and potential efficacy in patients with chemotherapy-refractory epithelioid pleural mesothelioma.

16 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
OHOmid Hamid
Omid Hamid
VEV. Ekström-Rydén
V. Ekström-Rydén
IMInderjit Mehmi
Inderjit Mehmi
DWD. Wang
D. Wang
MPM. Patel
M. Patel
GUGj Ullenhag
Gj Ullenhag
This phase I/II study evaluated the capacity of tumor microenvironment (TME) gene engineering by intratumoral injection of a viral vector encoding a designed CD40L and 4-1BBL combined with intravenous atezolizumab (anti-PD-L1 antibody) to induce immune activation in 24 patients with stage IV malignant melanoma refractory to PD-1 inhibition. Primary objective was tolerability. Tumor response, pharmacokinetics, and biomarker evaluations were secondary. Treatment was well-tolerated in both dose cohorts (1×10 11 and 5×10 11 viral particles). Th1 immune biomarkers was increased in the TME (NanoString) as well as in blood (Olink). In long-term survivors, we observed increased markers for T cell fitness and for the immunoproteasome. The overall response rate was 17% accordingly to RECIST 1.1 and disease control was noted in 54%. Forty-six percent of patients were still alive two years post enrollment. The lower dose showed very encouraging results with a median progression-free survival of 9.7 months and median overall survival of 26.3 months (post-hoc analyses). In conclusion, TME gene engineering may have re-sensitized refractory patients to checkpoint treatment or acted alone to control tumor growth. The small sample size and single arm design limits effect interpretation but the data shows promise for continued clinical investigation. Study registration: NCT04123470.

21 September 2021 in Annals of Oncology
Verified
Journal Article
Closed access
MPM. Patel
M. Patel
EFEudald Felip
Eudald Felip
RSR. Sharkey
R. Sharkey
MKMarco Krengli
Marco Krengli
JCJ.D. Chester
J.D. Chester
ACAlessio Cortellini
Alessio Cortellini

8 May 2018
Verified
Book Chapter
Closed access
MPMeera Patel
Meera Patel
NPNakul Patel
Nakul Patel
KLKevin Lewis
Kevin Lewis
RBRaman Bedi
Raman Bedi
GPGaman Patel
Gaman Patel
A health system is the totality of formal efforts, commitments, personnel, institutions, economic resources and research efforts that a nation, state or society devotes to illness, premature mortality, incapacitation, prevention, rehabilitation and other health-related problems. Pre- National Health Service (NHS) health care was fragmented, with little coordination and limited access. Patients' dental health has improved with the greater availability of services. Primary Care Trusts are NHS organisations whose main responsibilities are to improve the health of the community, develop primary and community health services and commission hospital care for their local population. The way health care is organised in a particular society or country affects the health and quality of life of that society and has an impact on the professional life of health care workers. The cyclic process can begin again with ever improving health care quality. The common problems with health care delivery are numerous.

25 November 2025
Verified
Other
Open access
UVUlka N. Vaishampayan
Ulka N. Vaishampayan
ATArchana Thakur
Archana Thakur
WCWei Chen
Wei Chen
ADAbhinav Deol
Abhinav Deol
MPMeera Patel
Meera Patel
LLLawrence G Lum
Lawrence G Lum
A and B. Evaluation of Vβ repertoire. The three distinct patterns were observed for Vβ repertoire in CD3+/IFN-γ+ T cells post IT. Pattern 1) the proportions of Vβ repertoire noticeably higher after IT relative to preIT PBMC (solid black arrows); Pattern 2) the proportions of Vβ repertoire that were marginally higher at mid- and/or post-IT relative to pre-IT PBMC (dashed black arrows); Pattern 3) large proportions of Vβ repertoire were either lower or similar at mid-IT or post-IT relative to preIT PBMC in all four patients tested. PreIT (pretherapy), midIT (preinfusion 5) postIT (1 week post infusion 8 of BATs).